Mignon L. Loh MD
Chief, Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy & Director, Ben Towne Center for Childhood Cancer
Join to View Full Profile
4800 Sand Point Way NEMB.8.501Seattle, WA 98105
Phone+1 206-987-2106
Dr. Loh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified pediatric hematologist-oncologist who specializes in the treatment of children, adolescents, and young adults with high risk leukemia. I am interested in harnessing genomics to add to the accurate diagnosis of leukemia and to utilize this knowledge for optimizing risk stratification and therapeutics.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1994
University of California (San Francisco)Internship, Pediatrics, 1991 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1991
Certifications & Licensure
CA State Medical License 1999 - 2027
WA State Medical License 2021 - 2026
MA State Medical License 1994 - 2001
NC State Medical License 1995 - 1998
NY State Medical License 1994 - 1996
CT State Medical License 1994 - 1995
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor sensitivity in T-cell acute lymphoblastic leukemiaJason Xu, Jonathan H Sussman, Austin Yang, Satoshi Yoshimura, Jianzhong Hu
Blood. 2025-03-18 - Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.Changya Chen, Jason Xu, Jonathan H Sussman, Tiffaney L Vincent, Joseph S Tumulty
Blood. 2025-03-16 - 1 citationsDNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.Carolin S Escherich, Takaya Moriyama, Zhenhua Li, Yu-Chih Hsiao, Wenjian Yang
Blood. 2025-03-13
Press Mentions
Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-cell ALL of Average or High Risk of RelapseJanuary 13th, 2025
Seattle Children’s Researchers Greatly Improve Survival for Children Diagnosed with the Most Common Form of Childhood Cancer, Changing the Standard of CareDecember 7th, 2024
Scientists Identify Genes Linked to Relapse in the Most Common Form of Childhood LeukemiaAugust 12th, 2024- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
